Market Cap 3.31M
Revenue (ttm) 11.42M
Net Income (ttm) -3.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -26.27%
Debt to Equity Ratio 0.00
Volume 93,000
Avg Vol 776,494
Day's Range N/A - N/A
Shares Out 9.75M
Stochastic %K 10%
Beta 0.76
Analysts Hold
Price Target $2.00

Company Profile

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also develops NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 215 702 8550
Website: nexgel.com
Address:
2150 Cabot Boulevard West, Suite B, Langhorne, United States
luckydog2
luckydog2 Sep. 4 at 5:05 PM
$NXGL Sequence LifeScience™ Names BIONX Surgical Exclusive U.S. Distributor for Eye Health Portfolio https://www.reddit.com/r/NXGL/s/tceU5Wu9Gr
0 · Reply
davooo
davooo Sep. 2 at 1:01 AM
$NXGL CELU is on a tear 🤺
0 · Reply
davooo
davooo Aug. 29 at 7:46 PM
$NXGL I voted NO! on everything 🧟
0 · Reply
BlindMonkey
BlindMonkey Aug. 24 at 5:47 PM
$NXGL To clarify the S-1 Pt. 3 6️⃣ NXGL still has major catalysts ahead. Strategic alternatives update expected in 30–45 days SilverSeal hospital launch (with reimbursement codes) BioNX Surgical backlog clearance Regenerative eye & aesthetics platform rollout Analyst PT: $2.00 7️⃣ Bottom line: The S‑1 is not new dilution, not toxic, and not a death spiral. It’s a standard resale registration for shares already owed from past deals. Bears are using it for FUD because they know NXGL has real catalysts coming. Do your own DD — but don’t let misinformation drive your decisions.
1 · Reply
BlindMonkey
BlindMonkey Aug. 24 at 5:45 PM
$NXGL To clarify the S-1 Pt. 2 4️⃣ NXGL shareholders blocked dilution AND blocked a reverse split. In June, shareholders rejected: increasing authorized shares from 25M → 100M any reverse split (1‑for‑2 to 1‑for‑10) NXGL cannot dilute at will. This is one of the cleanest micro‑cap floats on Nasdaq. 5️⃣ This S‑1 is normal housekeeping before strategic alternatives. NXGL formed a Strategic Alternatives & Value Creation Committee on Aug 20. Companies often clean up old financing obligations before announcing: a sale a merger an asset divestiture a recapitalization a strategic partnership This S‑1 is part of that process — not a red flag.
0 · Reply
BlindMonkey
BlindMonkey Aug. 24 at 5:42 PM
$NXGL to clarify the S-1 - Pt. 1 Use this exactly as‑is: $NXGL — Important Facts About the S‑1 (Ignore the FUD) A lot of bears are trying to spin the new Form S‑1 into fear, so here are the actual facts: 1️⃣ NXGL is NOT issuing new shares. The 15,252,337 shares in the S‑1 are NOT new dilution. They come from old convertible notes from April & May 2026 and the Celularity transaction. These shares already existed economically — the S‑1 just makes them legally sellable. 2️⃣ No warrants are included. This is huge. Most micro‑cap S‑1s include toxic warrant stacks. NXGL’s does not. This is a resale registration, not a toxic financing. 3️⃣ The S‑1 does NOT increase the float today. The float only increases if noteholders: convert their notes sell the shares The S‑1 does not force conversion and does not force selling. :
0 · Reply
lediemhang00
lediemhang00 Aug. 24 at 3:44 PM
$NXGL loaded some here. Still holding on to my $LUCY shares and $MGX after selling $MRNA last week
0 · Reply
LeverUp19
LeverUp19 Aug. 24 at 2:54 PM
$NXGL Really interesting today...Brian getting some of his rich buddies to get in?
0 · Reply
Nightwolf6502
Nightwolf6502 Aug. 24 at 9:19 AM
$NXGL Volume of 11M+ premarket. What the hell is this???
1 · Reply
premarketmaker
premarketmaker Aug. 24 at 8:58 AM
0 · Reply
Latest News on NXGL
NexGel downgraded to Hold from Buy at Maxim

2026-08-24T13:05:16.000Z - 11 days ago

NexGel downgraded to Hold from Buy at Maxim


NexGel downgraded to Hold from Buy at Maxim

2026-08-24T12:15:42.000Z - 11 days ago

NexGel downgraded to Hold from Buy at Maxim


NEXGEL Proxy statement: Proxy filing

Aug 24, 2026, 8:00 AM EDT - 11 days ago

NEXGEL Proxy statement: Proxy filing


NexGel announces strategic review

2026-08-20T20:20:37.000Z - 15 days ago

NexGel announces strategic review


NEXGEL Registration statement: Registration filing

Aug 20, 2026, 8:00 AM EDT - 15 days ago

NEXGEL Registration statement: Registration filing


NEXGEL Quarterly report: Q2 2026

Aug 17, 2026, 4:00 PM EDT - 18 days ago

NEXGEL Quarterly report: Q2 2026


NEXGEL Earnings release: Q2 2026

Aug 17, 2026, 4:00 PM EDT - 18 days ago

NEXGEL Earnings release: Q2 2026


NEXGEL Reports Second Quarter 2026 Financial Results

Aug 17, 2026, 8:00 AM EDT - 18 days ago

NEXGEL Reports Second Quarter 2026 Financial Results

NXGLW


NEXGEL Proxy statement: Proxy filing

Aug 14, 2026, 8:00 AM EDT - 21 days ago

NEXGEL Proxy statement: Proxy filing


NEXGEL Slides: Investor presentation

Jun 23, 2026, 7:00 AM EDT - 2 months ago

NEXGEL Slides: Investor presentation


NEXGEL Transcript: Planet MicroCap Las Vegas 2026

Jun 17, 2026, 4:30 PM EDT - 2 months ago

NEXGEL Transcript: Planet MicroCap Las Vegas 2026


NEXGEL Proxy statement: Proxy filing

Jun 9, 2026, 8:00 AM EDT - 2 months ago

NEXGEL Proxy statement: Proxy filing


NEXGEL Proxy statement: Proxy filing

May 29, 2026, 8:00 AM EDT - 3 months ago

NEXGEL Proxy statement: Proxy filing


NEXGEL Earnings Call Transcript: Q1 2026

May 15, 2026, 12:00 PM EDT - 3 months ago

NEXGEL Earnings Call Transcript: Q1 2026


NEXGEL Quarterly report: Q1 2026

May 15, 2026, 12:00 PM EDT - 3 months ago

NEXGEL Quarterly report: Q1 2026


NexGel appoints Ian Blackman as CFO

2026-04-27T13:38:27.000Z - 4 months ago

NexGel appoints Ian Blackman as CFO

CELU


NEXGEL Transcript: M&A announcement

Apr 21, 2026, 4:30 PM EDT - 4 months ago

NEXGEL Transcript: M&A announcement


NEXGEL Press release: M&A announcement

Apr 21, 2026, 4:30 PM EDT - 4 months ago

NEXGEL Press release: M&A announcement


NexGel closes acquisition of products from Celularity

2026-04-21T15:06:20.000Z - 4 months ago

NexGel closes acquisition of products from Celularity

CELU


NEXGEL Annual report: Q4 2025

Mar 31, 2026, 7:00 AM EDT - 5 months ago

NEXGEL Annual report: Q4 2025


NexGel price target lowered to $2 from $6 at Maxim

2026-03-12T13:15:47.000Z - 5 months ago

NexGel price target lowered to $2 from $6 at Maxim


NexGel announces financing of $1.797M relating to acquistion

2026-02-10T14:10:54.000Z - 6 months ago

NexGel announces financing of $1.797M relating to acquistion


NexGel to spin-off drug delivery program into NexGelRx

2025-12-11T13:15:18.000Z - 8 months ago

NexGel to spin-off drug delivery program into NexGelRx


NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx

Dec 11, 2025, 8:00 AM EST - 8 months ago

NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx


NEXGEL Earnings Call Transcript: Q3 2025

Nov 11, 2025, 4:30 PM EST - 9 months ago

NEXGEL Earnings Call Transcript: Q3 2025


NEXGEL Quarterly report: Q3 2025

Nov 11, 2025, 4:30 PM EST - 9 months ago

NEXGEL Quarterly report: Q3 2025


NEXGEL Earnings release: Q3 2025

Nov 11, 2025, 4:30 PM EST - 9 months ago

NEXGEL Earnings release: Q3 2025


NEXGEL Reports Third Quarter 2025 Financial Results

Nov 11, 2025, 4:10 PM EST - 9 months ago

NEXGEL Reports Third Quarter 2025 Financial Results


NEXGEL Proxy statement: Proxy Filing

Oct 30, 2025, 8:00 AM EDT - 10 months ago

NEXGEL Proxy statement: Proxy Filing


NEXGEL Transcript: LD Micro Main Event XIX Investor Conference

Oct 20, 2025, 2:30 PM EDT - 10 months ago

NEXGEL Transcript: LD Micro Main Event XIX Investor Conference


NEXGEL Proxy statement: Proxy Filing

Oct 20, 2025, 8:00 AM EDT - 10 months ago

NEXGEL Proxy statement: Proxy Filing


NEXGEL Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

NEXGEL Earnings Call Transcript: Q2 2025


NEXGEL Quarterly report: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

NEXGEL Quarterly report: Q2 2025


NEXGEL Earnings release: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

NEXGEL Earnings release: Q2 2025


NEXGEL Slides: Investor Presentation

Aug 12, 2025, 4:00 PM EDT - 1 year ago

NEXGEL Slides: Investor Presentation


NexGel appoints Steve Ciardiello to board of directors

2025-08-05T12:29:27.000Z - 1 year ago

NexGel appoints Steve Ciardiello to board of directors

SSTK


NEXGEL Earnings Call Transcript: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

NEXGEL Earnings Call Transcript: Q1 2025


NEXGEL Quarterly report: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

NEXGEL Quarterly report: Q1 2025


NEXGEL Earnings release: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

NEXGEL Earnings release: Q1 2025


NEXGEL Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

NEXGEL Proxy statement: Proxy Filing


NEXGEL Transcript: Planet MicroCap Showcase: VEGAS 2025

Apr 23, 2025, 12:30 PM EDT - 1 year ago

NEXGEL Transcript: Planet MicroCap Showcase: VEGAS 2025


NEXGEL Earnings Call Transcript: Q4 2024

Mar 24, 2025, 4:30 PM EDT - 1 year ago

NEXGEL Earnings Call Transcript: Q4 2024


NEXGEL Annual report: Q4 2024

Mar 24, 2025, 4:30 PM EDT - 1 year ago

NEXGEL Annual report: Q4 2024


NEXGEL Earnings release: Q4 2024

Mar 24, 2025, 4:30 PM EDT - 1 year ago

NEXGEL Earnings release: Q4 2024


NexGel expects to generate at least $13M in revenue in FY25

2025-01-22T14:10:46.000Z - 1 year ago

NexGel expects to generate at least $13M in revenue in FY25


NEXGEL Appoints Joseph F. McGuire as Chief Financial Officer

Jan 2, 2025, 9:00 AM EST - 1 year ago

NEXGEL Appoints Joseph F. McGuire as Chief Financial Officer


NEXGEL Earnings Call Transcript: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

NEXGEL Earnings Call Transcript: Q3 2024


NEXGEL Earnings release: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

NEXGEL Earnings release: Q3 2024


NEXGEL Quarterly report: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

NEXGEL Quarterly report: Q3 2024


NEXGEL Announces $2,000,000 Registered Direct Offering

Nov 11, 2024, 5:35 PM EST - 1 year ago

NEXGEL Announces $2,000,000 Registered Direct Offering


NEXGEL Appoints Kip Crecca to its Scientific Advisory Board

Oct 4, 2024, 9:00 AM EDT - 1 year ago

NEXGEL Appoints Kip Crecca to its Scientific Advisory Board


NEXGEL Earnings Call Transcript: Q2 2024

Aug 14, 2024, 4:30 PM EDT - 2 years ago

NEXGEL Earnings Call Transcript: Q2 2024


NEXGEL Quarterly report: Q2 2024

Aug 14, 2024, 4:30 PM EDT - 2 years ago

NEXGEL Quarterly report: Q2 2024


NEXGEL Earnings release: Q2 2024

Aug 14, 2024, 4:30 PM EDT - 2 years ago

NEXGEL Earnings release: Q2 2024


NEXGEL Acquires International Beauty Brand, Silly George

May 16, 2024, 9:00 AM EDT - 2 years ago

NEXGEL Acquires International Beauty Brand, Silly George


NEXGEL Earnings Call Transcript: Q1 2024

May 13, 2024, 4:30 PM EDT - 2 years ago

NEXGEL Earnings Call Transcript: Q1 2024


NEXGEL Quarterly report: Q1 2024

May 13, 2024, 4:30 PM EDT - 2 years ago

NEXGEL Quarterly report: Q1 2024


NEXGEL Earnings release: Q1 2024

May 13, 2024, 4:30 PM EDT - 2 years ago

NEXGEL Earnings release: Q1 2024


NEXGEL Proxy statement: Proxy Filing

May 3, 2024, 8:00 AM EDT - 2 years ago

NEXGEL Proxy statement: Proxy Filing


NEXGEL Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

NEXGEL Proxy statement: Proxy Filing


NEXGEL Earnings Call Transcript: Q4 2023

Apr 1, 2024, 8:30 AM EDT - 2 years ago

NEXGEL Earnings Call Transcript: Q4 2023


NEXGEL Earnings release: Q4 2023

Apr 1, 2024, 8:30 AM EDT - 2 years ago

NEXGEL Earnings release: Q4 2023


NEXGEL Annual report: Q4 2023

Apr 1, 2024, 8:30 AM EDT - 2 years ago

NEXGEL Annual report: Q4 2023


NEXGEL Earnings Call Transcript: Q3 2023

Nov 13, 2023, 4:30 PM EST - 2 years ago

NEXGEL Earnings Call Transcript: Q3 2023


NEXGEL Quarterly report: Q3 2023

Nov 13, 2023, 4:30 PM EST - 2 years ago

NEXGEL Quarterly report: Q3 2023


NEXGEL Earnings release: Q3 2023

Nov 13, 2023, 4:30 PM EST - 2 years ago

NEXGEL Earnings release: Q3 2023


NEXGEL Earnings Call Transcript: Q2 2023

Aug 14, 2023, 4:30 PM EDT - 3 years ago

NEXGEL Earnings Call Transcript: Q2 2023


NEXGEL Quarterly report: Q2 2023

Aug 14, 2023, 4:30 PM EDT - 3 years ago

NEXGEL Quarterly report: Q2 2023


NEXGEL Earnings release: Q2 2023

Aug 14, 2023, 4:30 PM EDT - 3 years ago

NEXGEL Earnings release: Q2 2023


NEXGEL Registration statement: Registration Filing

May 26, 2023, 8:00 AM EDT - 3 years ago

NEXGEL Registration statement: Registration Filing


NEXGEL Earnings Call Transcript: Q1 2023

May 15, 2023, 4:30 PM EDT - 3 years ago

NEXGEL Earnings Call Transcript: Q1 2023


NEXGEL Quarterly report: Q1 2023

May 15, 2023, 4:30 PM EDT - 3 years ago

NEXGEL Quarterly report: Q1 2023


NEXGEL Earnings release: Q1 2023

May 15, 2023, 4:30 PM EDT - 3 years ago

NEXGEL Earnings release: Q1 2023


NEXGEL Proxy statement: Proxy Filing

Apr 27, 2023, 8:00 AM EDT - 3 years ago

NEXGEL Proxy statement: Proxy Filing


NEXGEL Earnings Call Transcript: Q4 2022

Mar 27, 2023, 4:30 PM EDT - 3 years ago

NEXGEL Earnings Call Transcript: Q4 2022


NEXGEL Earnings release: Q4 2022

Mar 27, 2023, 4:30 PM EDT - 3 years ago

NEXGEL Earnings release: Q4 2022


NEXGEL Annual report: Q4 2022

Mar 27, 2023, 4:30 PM EDT - 3 years ago

NEXGEL Annual report: Q4 2022


luckydog2
luckydog2 Sep. 4 at 5:05 PM
$NXGL Sequence LifeScience™ Names BIONX Surgical Exclusive U.S. Distributor for Eye Health Portfolio https://www.reddit.com/r/NXGL/s/tceU5Wu9Gr
0 · Reply
davooo
davooo Sep. 2 at 1:01 AM
$NXGL CELU is on a tear 🤺
0 · Reply
davooo
davooo Aug. 29 at 7:46 PM
$NXGL I voted NO! on everything 🧟
0 · Reply
BlindMonkey
BlindMonkey Aug. 24 at 5:47 PM
$NXGL To clarify the S-1 Pt. 3 6️⃣ NXGL still has major catalysts ahead. Strategic alternatives update expected in 30–45 days SilverSeal hospital launch (with reimbursement codes) BioNX Surgical backlog clearance Regenerative eye & aesthetics platform rollout Analyst PT: $2.00 7️⃣ Bottom line: The S‑1 is not new dilution, not toxic, and not a death spiral. It’s a standard resale registration for shares already owed from past deals. Bears are using it for FUD because they know NXGL has real catalysts coming. Do your own DD — but don’t let misinformation drive your decisions.
1 · Reply
BlindMonkey
BlindMonkey Aug. 24 at 5:45 PM
$NXGL To clarify the S-1 Pt. 2 4️⃣ NXGL shareholders blocked dilution AND blocked a reverse split. In June, shareholders rejected: increasing authorized shares from 25M → 100M any reverse split (1‑for‑2 to 1‑for‑10) NXGL cannot dilute at will. This is one of the cleanest micro‑cap floats on Nasdaq. 5️⃣ This S‑1 is normal housekeeping before strategic alternatives. NXGL formed a Strategic Alternatives & Value Creation Committee on Aug 20. Companies often clean up old financing obligations before announcing: a sale a merger an asset divestiture a recapitalization a strategic partnership This S‑1 is part of that process — not a red flag.
0 · Reply
BlindMonkey
BlindMonkey Aug. 24 at 5:42 PM
$NXGL to clarify the S-1 - Pt. 1 Use this exactly as‑is: $NXGL — Important Facts About the S‑1 (Ignore the FUD) A lot of bears are trying to spin the new Form S‑1 into fear, so here are the actual facts: 1️⃣ NXGL is NOT issuing new shares. The 15,252,337 shares in the S‑1 are NOT new dilution. They come from old convertible notes from April & May 2026 and the Celularity transaction. These shares already existed economically — the S‑1 just makes them legally sellable. 2️⃣ No warrants are included. This is huge. Most micro‑cap S‑1s include toxic warrant stacks. NXGL’s does not. This is a resale registration, not a toxic financing. 3️⃣ The S‑1 does NOT increase the float today. The float only increases if noteholders: convert their notes sell the shares The S‑1 does not force conversion and does not force selling. :
0 · Reply
lediemhang00
lediemhang00 Aug. 24 at 3:44 PM
$NXGL loaded some here. Still holding on to my $LUCY shares and $MGX after selling $MRNA last week
0 · Reply
LeverUp19
LeverUp19 Aug. 24 at 2:54 PM
$NXGL Really interesting today...Brian getting some of his rich buddies to get in?
0 · Reply
Nightwolf6502
Nightwolf6502 Aug. 24 at 9:19 AM
$NXGL Volume of 11M+ premarket. What the hell is this???
1 · Reply
premarketmaker
premarketmaker Aug. 24 at 8:58 AM
0 · Reply
premarketmaker
premarketmaker Aug. 24 at 8:57 AM
$NXGL let the chart work - it is buidling
0 · Reply
premarketmaker
premarketmaker Aug. 24 at 8:56 AM
$NXGL early potential to .67 squeeze .75+
0 · Reply
premarketmaker
premarketmaker Aug. 24 at 8:49 AM
$NXGL keep an eye here for move over .50 8m float and this can move rapidly
0 · Reply
DylanGFM
DylanGFM Aug. 24 at 8:46 AM
0 · Reply
davooo
davooo Aug. 21 at 12:16 AM
$NXGL I'm holding 4800 shares @. 56
1 · Reply
davooo
davooo Aug. 20 at 11:43 PM
$NXGL At August 20, 2026, it is subject to completion, and the selling stockholders may not sell these shares under the prospectus until SEC effectiveness. It registers up to $15,252,337 common shares issuable on note conversion; no shares issuable on the related warrants are registered now. If the notes are converted and shares issued, the additional share count would reduce existing holders’ percentage ownership absent offsetting changes.
0 · Reply
davooo
davooo Aug. 20 at 11:42 PM
$NXGL. CONCLUSION: Positive None. Negative Substantial doubt about going concern: NexGel reports $0.5 million cash, a $4.5 million six‑month net loss, and $2.7 million operating cash use, and explicitly states substantial doubt about its ability to continue as a going concern. High dilution and financing overhang: Up to 15,252,337 new shares registered from convertibles, with full‑ratchet anti‑dilution and no floor on the $0.60 conversion price, plus potential additional issuances if authorized shares are increased
1 · Reply
davooo
davooo Aug. 20 at 11:39 PM
$NXGL NexGel, Inc. (NXGL) is registering 15,252,337 shares of common stock on Form S-1 for resale by existing investors. These shares are issuable upon conversion of unsecured convertible promissory notes from April and May 2026 financings and the Celularity-related transactions; no warrant shares are included. The company will receive no proceeds from these resales, though it will bear registration costs. As of August 20, 2026, NexGel had 9,747,663 shares outstanding out of 25,000,000 authorized, and states that full note and warrant conversion would exceed currently authorized shares. A special meeting on September 23, 2026 seeks approval to increase authorized common stock to up to 150,000,000 shares.
0 · Reply
davooo
davooo Aug. 20 at 11:38 PM
$NXGL NexGel, 10% interest (18% on default), mature in 18 months, and are initially convertible at $0.60 per share with full-ratchet anti-dilution and downward reset features that can significantly increase the number of shares issued if the market price falls. NexGel highlights a going concern uncertainty, with $0.5 million in unrestricted cash, a $4.5 million net loss, and $2.7 million operating cash outflow for the six months ended June 30, 2026. The company also notes that large resales of these shares could pressure its stock price and further dilute existing holders.
0 · Reply
LeverUp19
LeverUp19 Aug. 20 at 9:29 PM
$NXGL While I appreciate all of Adam's hard work, the reality is that he was not getting it done. Happy to hear the news this afternoon and excited about what this change will bring.
0 · Reply
OldManLogan
OldManLogan Aug. 20 at 8:35 PM
$NXGL Makes sense to me. Adam got in over his head. Leadership change brings clarity, but strategic review may still cause caution.
0 · Reply
luckydog2
luckydog2 Aug. 20 at 8:09 PM
$NXGL NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE https://ir.nexgel.com/news-events/press-releases/detail/127/nexgel-announces-leadership-transition-and-strategic-review
0 · Reply